

Sheet

of

PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

61800(71526)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete If Known Substitute for form 1449/PTO Application Number 10/511,111-Conf. #2257 SUPPLEMENTAL INFORMATION October 12, 2004 Filing Date DISCLOSURE STATEMENT BY First Named Inventor Koji Oida **APPLICANT** Art Unit N/A Examiner Name Not Yet Assigned (lies se many chasts se neroccard)

Attorney Docket Number

Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

		FOREIG	GN PATENT (OCUMENTS		_
Exami Initials	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁴ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	۲

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. 'Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. *Senter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Skind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

			NON PATENT LITERATURE DOCUMENTS			
Exar Initia	arhiner Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	CA Dermot Kearney and Desmond Fitzgerald: "The Anti-Thrombotic Effects of Statins" JOURNA OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 33, no.5, 1999, pages 1305-1307.					
		СВ	Anetta Undas and Others: "Simvastatin Depresses Blood Clotting by Inhibiting Activation of Prothrombin, Factor V, and Factor XIII and by Enhancing Factor Va Inactivation" CIRCULATION, vol. 103, 2001, pages 2248-2253.			
1	/	CC	Meade T.W., "Haemostatic System and Arterial Disease: Future Perspectives" FIBRINOLYSIS & PROTEOLYSIS, vol. 11, 1997, pages 167-171.			

^{*}EXAMINER: tritital if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	/Brian-Yong Kwon/	Date	12/14/2007
Signature	Penan Fong (Worl	Considered	12/14/2007
		Considered	

^{&#}x27;Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. #603451



PTC/SB/08a/b (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information untess it contains a valid CMB control number.

Sub	stitute for form 1449A/B/P	ro			Complete if Knowp
				Application Number	Not Yet Assigned 2
11	IFORMATION	N DI	SCLOSURE	Filing Date	Concurrently Herewith
S	TATEMENT I	BY A	APPLICANT	First Named Inventor	Koji Oida
				Art Unit'	N/A
	(Use as many sh	reets a:	s necessary) 	Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	61800(71526)

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

	FOREIGN PATENT DOCUMENTS								
Exami		Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,			
Initials		No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (ii known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T⁰		
/B	.K.	BΑ	WO-92/00325 A1	09-01-1992	Mochida Pharmaceutical Co., Ltd.				
		BB	WO-02/17913 A1	03-07-2002	Sankyo Company, Limited		T		
		ВС	WO-01/58491 A1	08-16-2001	Takeda Chemical Industries, Ltd.				

"EXA finer: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USP O Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Mind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

			NON PATENT LITERATURE DOCUMENTS	
Exa: Initia	niner Is	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		CA	H. Ando et al., Journal of Pharmacology and Experimental Therapeutics, 294(3):1043-1046 (2000).	
		СВ	M. Mathay, New England Journal of Medicine, 344(10):759-762 (2001).	
\square		CC	S. Morikawa et al., Journal of Atherosclerosis and Thrombosis, 9(4):178-183 (2002).	
_A		CD	M. Nakagawa, pp. 42-44 (2001).	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	/Brian-Yong Kwon/	Date	40/44/0007
Sionature	/Brian Tong (Worl)	Considered	12/14/2007
450007			The state of the s

^{&#}x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.